Vabysmo coverage guide: faricimab anti-VEGF/Ang-2 step therapy, Avastin-first policies, medical benefit billing, retina documentation, and reauthorization

Vabysmo (faricimab-svoa, Genentech/Roche) is the first bispecific antibody approved for ophthalmic use, simultaneously targeting vascular endothelial growth factor-A (VEGF-A) and angiopoietin-2 (Ang-2). It is FDA-approved for three retinal indications: neovascular (wet) age-related macular degeneration (nAMD), diabetic macular edema (DME), and macular edema following retinal vein occlusion (RVO). In April 2026, the FDA approved an updated label extending RVO treatment beyond six months, aligning the label with real-world clinical practice.

Vabysmo competes in a crowded anti-VEGF space against Avastin (bevacizumab, off-label), Eylea (aflibercept 2 mg), Eylea HD (aflibercept 8 mg), Lucentis (ranibizumab), and their biosimilars. Most payers impose step-therapy hierarchies that require Avastin first — and sometimes a ranibizumab biosimilar — before covering Vabysmo. Those step edits, combined with buy-and-bill reimbursement economics, create a specific access workflow for retina practices.

This guide covers Vabysmo's formulary positioning, step-therapy hierarchies, HCPCS coding, buy-and-bill vs specialty pharmacy models, reauthorization evidence, and patient support programs.

Short answer

Step-therapy hierarchies and Avastin-first policies

Step therapy is the primary access barrier for Vabysmo. Most payers tier anti-VEGF agents into preferred and non-preferred groups:

Typical tier structure

Payer-specific step-therapy policies

UnitedHealthcare (effective April 2026): UHC's commercial ophthalmologic VEGF inhibitor policy places Avastin and bevacizumab biosimilars as preferred (no PA). Vabysmo, Eylea HD, Beovu, and Pavblu are non-preferred Tier 2 agents requiring documentation of failure or intolerance to at least 3 months of Avastin. Eylea, Lucentis, and ranibizumab biosimilars are Tier 3, requiring failure of both Tier 1 and Tier 2 agents. For UHC Medicare Advantage (effective January 2026), step therapy is even more restrictive for non-AMD indications: the preferred pathway is Avastin first, then Eylea/Eylea HD/Pavblu, then Beovu/Byooviz/Cimerli/Lucentis/Susvimo/Vabysmo. This means Vabysmo requires failure of both Avastin and an aflibercept product for DME and RVO under UHC Medicare Advantage. For nAMD specifically, UHC Medicare places Eylea/Eylea HD/Pavblu as preferred over Vabysmo, requiring failure of one of those before covering Vabysmo.

Blue Cross Blue Shield of Massachusetts (Policy 092): Three-step hierarchy. Step 1: Avastin or bevacizumab biosimilar (no PA). Step 2: Vabysmo, Beovu, Eylea HD, or Pavblu — must have tried and failed at least 3 months of Avastin. Step 3: Eylea, Lucentis, Cimerli, Byooviz, or Susvimo — must have failed a Step 2 agent. All VEGF inhibitors require medical benefit billing only; not available for retail pharmacy billing.

Atrio Health Plans (2026 Part B step therapy form): Identical three-tier structure. Vabysmo classified as Group B (non-preferred) with 3-month Avastin trial required. Group C agents require prior failure of a Group B agent.

CarelonRx (effective July 2025): Avastin is preferred. Vabysmo, Eylea, Eylea HD, Lucentis, Cimerli, Byooviz, and Pavblu are all non-preferred and require prior Avastin failure.

Prime Therapeutics / Viva Health (reviewed May 2026): Vabysmo requires PA with initial 12-month authorization. Renewal every 12 months. Clinical criteria include documented nAMD, DME, or RVO diagnosis with no concurrent VEGF inhibitor use.

Strategies to navigate step therapy

1. Medical necessity for immediate Vabysmo: Document contraindication to Avastin (e.g., intraocular inflammation history, prior adverse reaction), or document that the clinical urgency of the retinal condition (e.g., rapid vision decline) makes a 3-month Avastin trial clinically inappropriate.
2. Intolerance documentation: If the patient experienced inflammation, increased IOP, or other adverse events on Avastin, document these specifically — not just "failed."
3. Use Genentech's sample appeal letter: Genentech provides a sample Avastin step-back appeal letter for Vabysmo at vabysmo-hcp.com. It cites the dual-pathway mechanism, extended dosing interval data, and cost savings from fewer injections.

HCPCS billing and coding

For Vabysmo: bill J2777 at 60 units (6 mg ÷ 0.1 mg per unit = 60 units) per intravitreal injection. Report one unit per treated eye; if both eyes are treated on the same date of service, append modifier LT (left) and RT (right) or bill on separate lines.

Buy-and-bill economics

Retina practices that purchase Vabysmo through authorized specialty distributors and bill J2777 bear the upfront inventory cost but gain scheduling flexibility. Key considerations:

• Reimbursement: Medicare Part B reimburses at ASP + 6% (or WAC-based rates for newer agents without established ASP). The ASP for J2777 has been declining as utilization increases.
• Margin pressure: the spread between acquisition cost and reimbursement has narrowed compared to launch-year economics. Practices must track ASP updates quarterly.
• Inventory management: Vabysmo single-dose vials and prefilled syringes require refrigeration (2°C–8°C). Prefilled syringes include a 30-gauge filter needle.

Specialty pharmacy model

Genentech Access Solutions coordinates with specialty pharmacies that ship Vabysmo to the practice for specific patients. Under this model:

• The specialty pharmacy bills the drug; the practice bills for the injection procedure and office visit.
• The practice avoids inventory cost but has less scheduling flexibility.
• Both models are available simultaneously — practices can buy-and-bill for some patients and use specialty pharmacy for others.

Indication-specific coverage criteria

Neovascular (wet) AMD (nAMD)

Most payers cover Vabysmo for nAMD when:

1. Diagnosis confirmed by fluorescein angiography and/or OCT showing choroidal neovascularization
2. Age 18+ (most plans)
3. Prescribed by an ophthalmologist or retina specialist
4. Step therapy met (Avastin trial and failure/intolerance)
5. No concurrent use of other VEGF inhibitors

Dosing: 6 mg every 4 weeks for the first 4 doses, then OCT and visual acuity evaluations at weeks 8 and 12 to determine whether to extend to q8, q12, or q16 weeks. In the TENAYA and LUCERNE trials, approximately 45% of patients achieved q16-week dosing at week 48.

Diabetic macular edema (DME)

Coverage criteria mirror nAMD with additional diabetes documentation:

1. DME diagnosis confirmed by OCT (central subfield thickness measurement)
2. Diabetes mellitus diagnosis documented (any type)
3. No active ocular/periocular infection or active intraocular inflammation
4. Not combined with other VEGF inhibitors

Dosing: two recommended regimens — (a) every 4 weeks for at least 4 doses, then extend; or (b) every 4 weeks for 6 doses, then q8 weeks. Some patients require continued q4-week dosing.

Macular edema following RVO

Updated in April 2026 with the new FDA-approved label allowing treatment beyond 6 months:

1. RVO diagnosis (branch or central) confirmed by fundus examination and OCT
2. Macular edema documented by central subfield thickness on OCT
3. No active infection or inflammation
4. Not combined with other VEGF inhibitors

Dosing: 6 mg every 4 weeks for 6 months. The April 2026 label update now allows continued treatment beyond 6 months based on clinical assessment, which aligns with how retina specialists were already managing RVO patients in practice.

ICD-10 codes

Reauthorization criteria

Initial authorization

Most plans grant 6 months of initial authorization for Vabysmo. Blue Cross Blue Shield of Massachusetts (Policy 092) and Prime Therapeutics (IC-0659) grant 12 months.

Reauthorization evidence

Continuation requires documented clinical benefit, typically evidenced by:

1. OCT improvement: reduction in central subfield thickness (CST) compared to baseline, or maintenance of achieved CST
2. Visual acuity: stable or improved best-corrected visual acuity (BCVA) measured by ETDRS letters or Snellen equivalent
3. No disease progression: OCT showing no new or worsening cystoid macular edema, subretinal fluid, or hemorrhage
4. Continued dosing at labeled intervals: documentation that the patient is being dosed per the FDA-approved label
5. No concurrent VEGF inhibitor: attestation that Vabysmo is the sole anti-VEGF agent being used

Patient support programs

Genentech Ophthalmology Access Solutions

• Benefit investigation: verifies coverage, PA requirements, and patient cost-sharing
• PA assistance: provides support for prior authorization submissions and appeals
• Specialty pharmacy coordination: identifies the required specialty pharmacy for the patient's plan
• Contact: (833) EYE-GENE / (833) 393-4363, Monday–Friday 6 AM–5 PM PST
• Website: gene.com/medical-professionals/medicines/vabysmo

Genentech copay programs (commercial patients only)

Two programs address drug and administration costs separately:

• Product Copay Program: covers out-of-pocket costs for Vabysmo itself for commercially insured patients. Maximum annual benefit applies. Not available for Medicare, Medicaid, TRICARE, or VA patients.
• Administration Copay Program: covers out-of-pocket costs for the administration of Vabysmo for commercially insured patients.

Genentech Patient Foundation

For uninsured or underinsured patients who meet income and other eligibility criteria, the Genentech Patient Foundation provides free Vabysmo. Contact: (888) 941-3331.

Financial assistance tool

Genentech offers an online financial assistance tool at vabysmo.com that walks patients through eligibility screening for all available programs.

Key documentation checklist for PA submission

1. OCT report showing central subfield thickness and qualitative assessment
2. Visual acuity measurement (ETDRS or Snellen)
3. Diagnosis confirmation (nAMD: fluorescein angiography; DME: OCT + diabetes documentation; RVO: fundus exam + OCT)
4. ICD-10 diagnosis codes for the retinal condition
5. Prior anti-VEGF treatment history (drug name, dates, number of injections, response/failure documentation)
6. If step therapy: documentation of ≥ 3 months of Avastin trial with clinical rationale for switching
7. Prescriber specialty documentation (ophthalmologist or retina specialist)
8. No active ocular/periocular infection or active intraocular inflammation
9. Attestation that Vabysmo will not be combined with other VEGF inhibitors
10. Correct HCPCS code J2777 with unit count (60 units per 6 mg dose)

Sources

• FDA. Vabysmo (faricimab-svoa) Prescribing Information. April 2026. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761235s000lbl.pdf
• Genentech. Vabysmo Payer Coverage Guide. https://www.vabysmo-hcp.com/content/dam/gene/vabysmo-hcp/pdfs/vabysmo-payer-coverage.pdf
• Genentech. Vabysmo Sample Avastin Step-Back Appeal Letter. https://www.vabysmo-hcp.com/content/dam/gene/vabysmo-hcp/pdfs/vabysmo-sample-avastin-step-back-appeal.pdf
• CMS / National Government Services. Billing and Coding: Ranibizumab and biosimilars, Aflibercept, Aflibercept HD, Brolucizumab-dbll, Faricimab-svoa. Local Coverage Article A52451. Updated March 2026. https://www.cms.gov
• UnitedHealthcare. Ophthalmologic VEGF Inhibitors Commercial Medical Benefit Drug Policy. Effective April 2026. https://www.uhcprovider.com/content/dam/provider/docs/public/policies/comm-medical-drug/ophthalmologic-vegf-inhibitors.pdf
• Blue Cross Blue Shield of Massachusetts. Drugs for Macular Degeneration and Diabetic Eye Disease, Policy 092. https://www.bluecrossma.org/medical-policies/sites/g/files/csphws2091/files/acquiadam-assets/092%20Drugs%20for%20Macular%20Degeneration%20and%20Diabetic%20Eye%20Disease.pdf
• Cigna Healthcare. Faricimab-svoa Coverage Policy IP0542. https://static.cigna.com/assets/chcp/pdf/coveragePolicies/pharmacy/ip_0542_coveragepositioncriteria_faricimab.pdf
• CarelonRx. VEGF Inhibitors Step Therapy Clinical Criteria CC-0072. https://www.carelonrx.com/ms/pharmacyinformation/VEGF.pdf
• Prime Therapeutics / Viva Health. Vabysmo (faricimab-svoa) Policy IC-0659. Last reviewed May 2026. https://www.vivahealth.com/files/medicare/policies/085
• Genentech. FDA Approves Updated VABYSMO Label to Extend Treatment for Macular Edema Following RVO Beyond Six Months. April 9, 2026. https://www.gene.com/media/statements/ps_040926